Roche, Johnson & Johnson, and Teva have demonstrated formidable deal making for many years. But generally, business development capabilities in the pharma industry remain very patchy, with the number of poor performers far out-weighing the good.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial